Chembio Diagnostic Systems, Inc.’s DPP® HIV 1/2 Assay, SURE CHECK® HIV 1/2, HIV 1/2 STAT-PAK®, and HIV 1/2 STAT-PAK® DIPSTICK tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2.
The standard screening test for antibodies to HIV is the enzyme immunoassay (EIA) or ELISA. This test requires two visits to a clinic or medical facility – something that is not always feasible. Rapid, point-of-care (POC) tests have been developed which produce results within 20 minutes or less and are less costly for testing agencies to perform due to the fewer outreach visits required to deliver results. Also, studies have shown that rapid tests are as sensitive and specific as conventional immunoassays.
Utilizing Chembio’s patented Dual Path Platform technology, DPP® Syphilis Screen & Confirm permits the simultaneous yet separate detection of both Trep and non-Trep markers at the point-of-care. The test format allows use in point-of-care settings, therefore represents a considerable advance in diagnosis as well as in time to treatment and ease of use.
Standard diagnosis of Syphilis is currently done using two different laboratory-based serologic tests, namely a non-treponemal screening test, usually either the Rapid Plasma Reagin (RPR) or Venereal Disease Research Laboratory (VDRL), followed by a more specific treponemal confirmatory (EIA) assay. Chembio has developed the first dual non-Treponemal & Treponemal POC Syphilis test.
Syphilis, caused by the bacterial spirochete Treponema pallidum, is a significant source of human morbidity and mortality worldwide. In fact, it is estimated that there are over 12 million cases of Syphilis occurring worldwide every year.
Chembio Diagnostic Systems, Inc.’s Chagas STAT-PAK® Assay is easy-to-perform, requires no cold chain storage, uses a minimal sample size, and provides visual detection of antibodies to T. cruzi.
Because traditional testing methods require laboratory equipment and storage, they aren’t effective methods in the more rural areas where Chagas is most common.
Recognized as one of the world’s neglected diseases, Chagas is a major public health concern in Latin America and is a growing concern in the United States and regions of Europe as the number of infected immigrants increase. Chagas is transmitted by Trypanosoma cruzi, a protozoan parasite of the hematophagous triatomine insect, and may cause cardiomyopathy, syndromes of the esophagus and colon, and eventually in chronic myocarditis resulting in high morbidity and mortality. It is curable if detected and treated early, but there is no effective treatment once it has become chronic.